Novartis Obtains Japanese Price Listing For Ilaris After Brief Delay
This article was originally published in PharmAsia News
Japan’s Social Central Medical Insurance Agency (Chuikyo) approved the price listing for Novartis AG's Ilaris (canakinumab) for rare inflammation, cryopyrin-associated periodic syndrome Nov. 18.
You may also be interested in...
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.
Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway